Jinyi W. Xu

639 Longmian Avenue
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A Inhibitor Discovery.

From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A Inhibitor Discovery.

Journal: Journal of medicinal chemistry

Published: July 20, 2026

Discovery of Novel HPK1 Inhibitors via Chemistry-Based Direct-to-Bioassay Screening and SAR Optimization.

Discovery of Novel HPK1 Inhibitors via Chemistry-Based Direct-to-Bioassay Screening and SAR Optimization.

Journal: Journal of medicinal chemistry

Published: March 13, 2026

Discovery of Novel Snail Inhibitors Derived from Omeprazole for Antiatherosclerotic Therapy: A Structure-Based Approach.

Discovery of Novel Snail Inhibitors Derived from Omeprazole for Antiatherosclerotic Therapy: A Structure-Based Approach.

Journal: Journal of medicinal chemistry

Published: February 10, 2026

Relationship between childhood trauma and depressive symptoms in adolescents with major depressive episodes and the mediating roles of perceived stress and abnormal brain structural development

Relationship between childhood trauma and depressive symptoms in adolescents with major depressive episodes and the mediating roles of perceived stress and abnormal brain structural development

Journal: Zhonghua yi xue za zhi

Published: February 05, 2026

Discovery of SY-589, a Highly Potent and Orally Bioavailable Polθ Helicase Inhibitor for the Treatment of HR-Deficient Tumors.

Discovery of SY-589, a Highly Potent and Orally Bioavailable Polθ Helicase Inhibitor for the Treatment of HR-Deficient Tumors.

Journal: Journal of medicinal chemistry

Published: January 23, 2026

Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.

Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: January 21, 2026

Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance.

Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance.

Journal: Journal of medicinal chemistry

Published: December 05, 2025

Targeting ClpP Protease: Emerging Therapeutic Strategies and Small-Molecule Modulators in Drug Discovery.

Targeting ClpP Protease: Emerging Therapeutic Strategies and Small-Molecule Modulators in Drug Discovery.

Journal: Medicinal research reviews

Published: December 02, 2025

A photoactivatable prodrug strategy toward spatially targeted inhibition of POLRMT for anticancer therapy.

A photoactivatable prodrug strategy toward spatially targeted inhibition of POLRMT for anticancer therapy.

Journal: European journal of medicinal chemistry

Published: October 28, 2025

Recent Advances on the Molecular Mechanisms of Apoptosis Induced by Natural Product Oridonin and Its Derivatives.

Recent Advances on the Molecular Mechanisms of Apoptosis Induced by Natural Product Oridonin and Its Derivatives.

Journal: Archiv der Pharmazie

Published: October 22, 2025

Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer.

Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: October 13, 2025

Bioorthogonal Chemistry: An Emerging Strategy for Targeted Protein Degradation.

Bioorthogonal Chemistry: An Emerging Strategy for Targeted Protein Degradation.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: September 18, 2025

Showing 1-12 of 124

Last Updated: 09/26/2026